ThisCART19A by Suzhou Fundamenta Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

Brain drain, skills loss, and other unintended consequences of overturning Roe v. Wade

Every day at the Kansas clinic where I perform abortions, I take care of pregnant people who have driven 10 hours or more across state

September 21, 2023

J&J wins FDA approval for Varipulse PFA system

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Johnson & Johnson received Food

November 7, 2024

Galen robot gets FDA de novo clearance for ENT surgeries

Dive Brief: Galen Robotics, a startup founded in 2016 to commercialize the work of a lab at Johns Hopkins University, said its surgical robot has

September 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.